Over the last few years, pharmaceutical companies have dumped millions into TV spots advertising therapies to help men with “Low T.” Any guy who’s watched a sporting event in the last 3 years is probably pretty familiar with the outlandish promises to “regain their youth” from the use of a simple gel or patch, that their doctor would be only too happy to prescribe.
It’s a compelling pitch, after all, what 35 year-old man wouldn’t like to feel 22 again? Commercials showing silver-haired guys playing flag football or flirting with the attractive blonde at a nice restaurant certainly give off a positive impression of the use of these drugs (called “testosterone replacement therapy” in medical parlance, but simply “Low-T” products by the advertisers). So what if you’ve never heard of a “disease” like low-T, or suspected maybe getting older is just a fact of life? For the pharma companies pitching these products, the lack of any actual disease to cure doesn’t mean there isn’t a market. And a market is what they’ve created, to the tune of $1.2 billion in sales of Low-T products in 2014 alone. But that artificial market has come at a cost, and that cost could very well be the health of the very men the marketing is aimed at.
A study published in the Journal of the American Medical Association (JAMA) in November of 2013 reported that recent clinical research showed a link between testosterone replacement therapy and heart attack. There has been a 30 percent rise in risk for stroke, heart attack, and death in men age 60 and older who had been prescribed testosterone, compared to those who were not prescribed TRT. Then, the FDA released a second safety announcement in January of 2014 stating they were investigating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products due to the rising reports from users and their doctors. Now, a report out this week from the FDA is recommending updated warnings be added to all low-T products (including the market leader Androgel) to provide further warnings to men about the serious increased risks of heart attack, stroke, and other cardiovascular problems.
There already exists a large class action suit against the makers of low-T drugs, with multi-district litigation involving over 200 named victims currently progressing in federal court in Illinois. Several mass tort firms and bad-drug lawyers are handling case inquiries for new victims of cardiovascular side effects from men who claim that the drug’s advertising hid the risks and minimized the warnings to doctors in order to maintain skyrocketing sales figures. While litigation may take years to finish, it’s clear now that it’s a “buyer beware” market hiding behind the slick packaging and glossy advertising pushing Low-T products on an unsuspecting audience.


  1. Its funny to watch a baseball game, and see one commercial for Androgel, followed immediately by another commercial for some law firm suing low t companies like Androgel.


  2. i used low-t gel for a while until my dr told me the risks were not worth it and to stop.


Leave a Reply

Your email address will not be published. Required fields are marked *